An observational study in Covid19, Systemic Autoimmune Disease and Inflammatory Rheumatism, sponsored by University Hospital, Lille. Terminated at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-13.
Sponsored by University Hospital, Lille · Observational
this observational, cross-sectional, national, comparative study, including RMD patients followed in hospital centres of the FAI²R Rare Diseases Healthcare Pathway network and specialist private practitioners caring for patients suffering from inflammatory rheumatism, systemic autoimmune diseases and auto-inflammatory diseases. The objective of the study is to compare RMD patients with COVID 19 infection (cases) to RMD patients who have not had COVID 19 infection (controls) on their mental health.
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's enrollment of 296 is above the median of 261 across 3,136 observational studies indexed under COVID-19.
Browse COVID-19 studies →University Hospital, Lille is the lead sponsor of 625 studies on the registry; 141 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients will be recruited from the French RMD covid19 cohort (ClinicalTrials.gov Identifier: NCT04353609) including patients from hospitals in the FAI²R Rare Diseases Healthcare Pathway network and specialist private practitioners (rheumatologists, internists with mixed hospital and private practice activities) caring for patients with inflammatory rheumatism, systemic autoimmune diseases and auto-inflammatory diseases.
Patient case:
Patient control:
Exclusion Criteria:
RMD patients with COVID 19 infection
RMD patients without COVID 19 infection
Frequency of PTSD depending on whether or not autoimmune patients have experienced COVID
Time frame: at one month following exposure to the traumatic factor (i.e. one month from COVID-19 infection
Severity of PTSD depending on whether or not autoimmune patients have experienced COVID
Time frame: at one month following exposure to the traumatic factor (i.e. one month from COVID-19 infection
This study is terminated, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Lille